PIK3CA-activated mutation

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
3 Unique sponsors
3 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Phase II: 2 Phase I: 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II

2 trials
  • Relay Therapeutics Inc. Commercial
    RLY-2608
    2024-518895-30-00 7 countries 2025 n=99
    Recruiting
  • BOOG Study Center B.V. Academic
    ALPELISIB; ALPELISIB, ALPELISIB
    2024-514965-20-00 1 country 2022 n=130
    Ended

Phase I

1 trial
  • Genentech Inc. Commercial
    IMP not specified
    2023-508124-36-00 1 country 2024 n=41
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Genentech Inc. Commercial 1 Phase I 0
Relay Therapeutics Inc. Commercial 1 Phase II 1
BOOG Study Center B.V. Academic 1 Phase II 0
New trials by year
2022
1
2024
1
2025
1
← All indication landscapes